Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 108, Issue 3, 2015, Pages e42-e45

  Maeda, Hajime ^a   Kubota, Akira ^a   Kanamori, Akira ^a   Tanaka, Yasushi ^b   Terauchi, Yasuo ^c   Matsuba, Ikuro ^a  

^a Kanagawa Physicians Association   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Creatinine; Dipeptidyl peptidase 4 (DPP 4) inhibitor; HbA1c; Sitagliptin

Indexed keywords

CREATININE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT DISORDER; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS; TREATMENT DURATION; UPREGULATION; WEIGHT GAIN; AGED; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGY; ETHNOLOGY; JAPAN; METABOLISM; MULTICENTER STUDY;

AGED; CREATININE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE;

EID: 84930179980     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.03.008     Document Type: Article

References (11)

1. Maeda H., Kubota A., Tanaka Y., Terauchi Y., Matsuba I., ASSET-K Study group The Safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 2012, 95(1):e20-e22.
2. Kubota A., Maeda H., Kanamori A., Tanaka Y., Terauchi Y., Matsuba I. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. J Diabetes Investig 2012, 3(6):503-509.
3. Kubota A., Maeda H., Kanamori A., Matoba K., Jin Y., Minagawa F., et al. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res 2012, 4(5):309-313.
4. Maeda H., Kubota A., Tanaka Y., Terauchi Y., Matsuba I. Long-term efficacy and safety of sitagliptin in the treatment of Japanese type 2 diabetes (ASSET-K1) to a target of HbA1c <7%. J Endocrinol Invest 2013, 36:568-573.
5. Takihata M., Nakamura A., Tajima K., Inazumi T., Komatsu Y., Tamura H., et al. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial. Diabetes Obes Metab 2013, 15(5):455-462.
6. Engel S.S., Round E., Golm G.T., Kaufman K.D., Goldstein B.J. Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. Diabetes Ther 2013, 4(1):119-145.
7. Arjona Ferreira J.C., Marre M., Barzilai N., Guo H., Golm G.T., Sisk C.M., et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2013, 36(5):1067-1073.
8. Carraro-Lacroix L.R., Malmic G., Girardi A.C. Regulation of Na+/H+ exchange NHE3 by glucagon-like-peptide-1 receptor agonist extendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 2009, 297:F1647-F1655.
9. Tanaka T., Higashijima Y., Wada T., Nangaku M. The potential for renoprotection with incretin-based drugs. Kidney Int 2014, 86:701-711.
10. Katsuya T., Ishikawa K., Sugimoto K., Rakugi H., Ogihara T. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. Hypertens Res 2003, 26(7):521-525.
11. Park H., Park C., Kim Y., Rascati K. Efficacy and study of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Diabetes 2012, 46:1543-1569.